Drug Type Small molecule drug |
Synonyms Ompenaclid Succinate, RGX 202, RGX-202 + [1] |
Target |
Mechanism SLC6A8 inhibitors(Creatine transporter inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC12H24N6O8 |
InChIKeyBLZFAXMHFJUYRF-UHFFFAOYSA-N |
CAS Registry2106793-65-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Ompenaclid | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic colon cancer | Phase 2 | BE | 10 Oct 2023 | |
Metastatic colon cancer | Phase 2 | FR | 10 Oct 2023 | |
Metastatic colon cancer | Phase 2 | ES | 10 Oct 2023 | |
RAS mutant Colorectal Cancer | Phase 2 | US | 01 Jun 2023 | |
KRAS mutation-related tumors | Phase 1 | US | 05 Jun 2018 | |
Metastatic Colorectal Carcinoma | Phase 1 | US | 05 Jun 2018 | |
Stomach Cancer | Phase 1 | US | 05 Jun 2018 |
NCT03597581 (ESMO2024) Manual | Phase 1/2 | 51 | tgjdcvihlr(qxqgcwsjbs) = ennbxuntvv mvyyirfpon (ahfznpajqg ) View more | Positive | 16 Sep 2024 | ||
tgjdcvihlr(qxqgcwsjbs) = lzwvojnufa mvyyirfpon (ahfznpajqg ) View more | |||||||
Corporate Publications Manual | Phase 2 | 41 | lfiglgcbbv(ibqoloikyp) = ufaqxzfome ncelsbegvt (gddhryspul ) View more | Positive | 04 Jan 2024 | ||
Phase 1/2 | 33 | vgmowmnroy(uostbpgzgq) = nausea (50%), diarrhea (44%) osiijxnywr (fvwwahziqb ) View more | Positive | 22 Oct 2023 | |||
(RASm) | |||||||
Phase 1 | Advanced Colorectal Adenocarcinoma Second line | 17 | awnvilrkwo(kmbrwzyfpe) = aslxktisdt nibuchhjdn (obuafvrhlj ) View more | Positive | 02 Jul 2022 | ||
awnvilrkwo(kmbrwzyfpe) = rtayvniuag nibuchhjdn (obuafvrhlj ) View more | |||||||
Phase 1 | Advanced Colorectal Adenocarcinoma Second line | - | xybwrvvnzu(wximvlujne) = 2 events (neutropenia, pulmonary embolus) niqojgjbbq (kzjjscotlg ) View more | Positive | 02 Jun 2022 | ||
NCT03597581 (ASCO2022) Manual | Phase 1 | 16 | (dose escalation) | ircerczzpc(jtmufzlhhh) = hfpozhhoua dehlxpmxdn (ngmhcvglwq ) View more | Positive | 02 Jun 2022 | |
(dose expansion) | - | ||||||
Not Applicable | - | RGX-202 gene therapy | aaopdrpavs(zkehribeou) = hwighgwljm psvzyfiuvt (utfnzebgzo ) | - | 13 Mar 2022 | ||
Phase 1 | 17 | FOLFIRI+RGX-202 | vjcpcbfigi(asdyeaznmf) = Not reached hoitfpvmmu (seyocpfqem ) View more | Positive | 29 May 2020 |